Optimizing the Assessment of Refractive Outcomes After Cataract Surgery

Subjects will be implanted with ACRYSOF® IQ Monofocal IOL Model SN60WF. Standard clinical
practice will be followed for pre-operative testing, IOL power estimation and IOL
implantation. Only one eye will be enrolled in the study per surgeon determination. The eye
will undergo both an automated and manual manifest refraction assessment at 3 months
postoperative.

Inclusion Criteria:

- Able to understand and sign an Ethics Committee/Institutional Review Board approved
Informed Consent;

- Willing and able to attend all scheduled study visits as required per protocol;

- Diagnosed with cataract in one or both eyes;

- Planned cataract removal by phacoemulsification with implantation of a monofocal IOL;
laser refractive procedures for incisions (primary and sideport), capsulorhexis and
lens fragmentation are allowed;

- Preoperative keratometric astigmatism ≤ 1.0 diopter (D);

- Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

- Women of childbearing potential, pregnant, or breast-feeding;

- History of ocular pathology, ocular inflammation, or ocular conditions, as specified
in the protocol;

- Previous intraocular or corneal surgery;

- Use of systemic medications that, in the opinion of the Investigator, may confound the
outcome or increase the risk of complications to the subject;

- Any medical condition that, in the opinion of the Investigator, may confound the
results of this study, prohibit the completion of the study assessments, or increase
the risk for the subject;

- Other protocol-defined exclusion criteria may apply.